Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis

Bone Marrow Transplantation volume 32, pages 771–775 (2003)Cite this article

Summary:

The effect of hematopoietic growth factors on neutrophil recovery after allogeneic transplantation is well-recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of GVHD is unclear. We performed a meta-analysis to determine the effect of G–CSF or GM-CSF on the risk of nonhematopoietic outcomes after allogeneic transplantation. A search of the literature from 1986 to present yielded 18 publications in which data were provided for cohorts receiving growth factor vs either placebo or no therapy. These included nine prospective randomized studies, eight retrospective cohort studies, and one case–control study comprising a total of 1198 patients. The publication types were heterogeneous with regard to demographic and treatment characteristics, although within publications, comparative groups were generally balanced. The pooled risk ratio estimates with use of growth factor was 1.08 (95% CI 0.87–1.33, P=0.48) for grades 2–4 acute GVHD, 1.22 (95% CI 0.80–1.86, P=0.99) for grades 3–4 acute GVHD, and 1.02 (95% CI 0.82–1.26, P=0.87) for chronic GVHD. This analysis did not detect a significant change in the risk of acute or chronic GVHD after allogeneic hematopoietic stem cell transplantation when hematopoietic growth factors were used to shorten the initial period of neutropenia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kitayama H, Ishikawa J, Yamagami T et al. Granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Jpn J Clin Oncol 1989; 19: 367–372.

    CAS  PubMed  Google Scholar 

  2. Masaoka T, Moriyama Y, Kato S-I et al. A double-blind controlled study of KRN 8601 (G-CSF) in patients who received allogeneic bone marrow transplantation. Transplant Now 1990; 3: 233–239.

    Google Scholar 

  3. Asano S, Masaoka T, Takaku F . Clinical effect of recombinant human granulocyte colony-stimulating factor in bone marrow transplantation. Jpn J Cancer Chemother 1990; 17: 1201–1209.

    CAS  Google Scholar 

  4. Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–1420.

    Article  CAS  PubMed  Google Scholar 

  5. De Witte T, Gratwohl A, Van Der Lely N et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359–1365.

    CAS  PubMed  Google Scholar 

  6. Schriber JR, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680–1684.

    CAS  PubMed  Google Scholar 

  7. Gisselbrecht C, Prentice HG, Baciagalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696–700.

    Article  CAS  PubMed  Google Scholar 

  8. Hiraoka A, Masaoka T, Mizoguchi H et al. Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled Phase III clinical trial. Jpn J Clin Oncol 1994; 24: 205–211.

    CAS  PubMed  Google Scholar 

  9. Nemunaitis J, Rosenfeld CS, Ash R et al. Phase III randomized, double-blind placebo-controlled trial of GM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–954.

    CAS  PubMed  Google Scholar 

  10. Martin-Agarra S, Bishop MR, Tarabtolo S et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-versus-host disease prophylaxis. Exp Hematol 1995; 23: 1503–1508.

    Google Scholar 

  11. Hiraoka A, Masaoka T, Shibata H et al. Five years follow-up of a randomized placebo-controlled study with filgrastim (recombinant human granulocyte colony-stimulating factor) in patients receiving allogeneic bone-marrow transplantation. Blood 1995; 86: 222a (Abstr. 874).

    Google Scholar 

  12. Locatelli F, Pession A, Zecca M et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996; 17: 31–37.

    CAS  PubMed  Google Scholar 

  13. Xiaojun H, Nailan G, Yunming F, Daopei L . Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Chinese Med J 1996; 109: 827–831.

    Google Scholar 

  14. Saarinen UM, Hovi L, Juvonen E et al. Granulocyte colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Ped Oncol 1996; 26: 380–386.

    Article  CAS  Google Scholar 

  15. Lee SJ, Weller E, Alyea EP et al. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 1998; 92: 2725–2729.

    CAS  PubMed  Google Scholar 

  16. Berger C, Bertz H, Schmoor C et al. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 1999; 23: 983–990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Madero L, Diaz MA, Ortega JJ et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematol 1999; 84: 133–137.

    CAS  Google Scholar 

  18. Stinson TJ, Adams JR, Bishop MR et al. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 663–666.

    Article  CAS  PubMed  Google Scholar 

  19. Bishop MR, Tarantolo SR, Geller RB et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80–85.

    CAS  PubMed  Google Scholar 

  20. Przepiorka D, Smith TL, Folloder J et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405–3410.

    Article  CAS  PubMed  Google Scholar 

  21. Trigg ME, Peters C, Zimmerman MB . Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial. Ped Transplant 2000; 4: 123–131.

    Article  CAS  Google Scholar 

  22. Ozcan M, Ustun C, Akcaglayan E et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: 499–505.

    Article  CAS  PubMed  Google Scholar 

  23. Gyger M, Stuart RK, Perreault C . Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000; 26: 1–16.

    Article  CAS  PubMed  Google Scholar 

  24. Grant SM, Heel RC . Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43: 516–560.

    Article  CAS  PubMed  Google Scholar 

  25. Petitti DB. Meta Analysis, Decision Analysis and Cost-Effectivenesss Analysis: Methods for Quantitative Synthesis in Medicine, 2nd edn. Oxford University Press: New York, 2000, pp 95–116.

    Google Scholar 

  26. Begg CB, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.

    Article  CAS  PubMed  Google Scholar 

  27. Egger M, Davey SG, Schneider M et al. Bias in meta-analysis detected by a simple graphical test. Br Med J 1995; 315: 629–634.

    Article  Google Scholar 

  28. Ferrara JL . Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299–306.

    Article  CAS  PubMed  Google Scholar 

  29. Blazar BR, Widmer MB, Soderling CC et al. Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte-macrophage colony-stimulating factor. Blood 1988; 71: 320–328.

    CAS  PubMed  Google Scholar 

  30. Schuening FG, Storb R, Goehle S et al. Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplant in dogs. Blood 1990; 76: 636–640.

    CAS  PubMed  Google Scholar 

  31. Atkinson K, Matias C, Guiffre A et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376–1382.

    CAS  PubMed  Google Scholar 

  32. Reddy V, Hill G, Pan L et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation 2000; 69: 691–693.

    Article  CAS  PubMed  Google Scholar 

  33. Tanaka J, Imamura M, Kasai M et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. Eur J Haematol 1996; 57: 111–113.

    Article  CAS  PubMed  Google Scholar 

  34. Foster PF, Mital D, Sankary HN et al. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995; 59: 1557–1563.

    Article  CAS  PubMed  Google Scholar 

  35. Winston DJ, Foster PF, Somberg KA et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999; 68: 1298–1304.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA

    V T Ho, T Okamura & D Przepiorka

  2. MedStats International, Houston, TX, USA

    N Q Mirza

  3. the University of Texas School of Public Health, Houston, TX, USA

    D del Junco

Authors
  1. V T Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Q Mirza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D del Junco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Przepiorka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Przepiorka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ho, V., Mirza, N., del Junco, D. et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 32, 771–775 (2003). https://doi.org/10.1038/sj.bmt.1704228

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704228

Keywords

This article is cited by

Search

Advanced search

Quick links